Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases

ABSTRACT

The disclosure is concerned with a novel human intestinal isolate capable of converting L-lysine into butyrate and/or of converting fructose-lysine into butyrate. The novel isolate can be used as a probiotic or supplement to promote production of butyrate in the GI tract, thereby preventing and/or treating conditions or diseases that benefit from the production of butyrate. Additionally, the isolate may prevent and/or treat conditions or diseases caused by an excess of pathogenic bacteria in the GI tract, mediated by L-lysine, or mediated by fructose-lysine or other advanced glycation end products.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a national phase entry under 35 U.S.C. § 371 ofInternational Patent Application PCT/EP2016/050310, filed Jan. 8, 2016,designating the United States of America and published in English asInternational Patent Publication WO 2016/110585 A1 on Jul. 14, 2016,which claims the benefit under Article 8 of the Patent CooperationTreaty to European Patent Application Serial No. 15150701.9, filed Jan.9, 2015.

TECHNICAL FIELD

This disclosure relates to the fields of intestinal microbiota,metabolic conversions and pharmaceutical, food, or feed compositionscomprising bacteria. More specifically, the disclosure provides a newintestinal bacterial strain isolated from a human, i.e., a humanintestinal isolate, which is capable of converting L-lysine intobutyrate, and which is further capable of converting glycated lysineinto butyrate. Compositions comprising the intestinal bacterial strainand methods employing the intestinal bacterial strain are also provided.

BACKGROUND

The human gastrointestinal (GI) tract is inhabited by more than 100trillion microorganisms (i.e., bacteria, archaea, fungi and viruses),which altogether form the so-called “gastrointestinal microbiota” (GImicrobiota). The GI microbiota benefit from the host (e.g., human being)by being provided with substrates for fermentation that are eitheringested by the host via the diet or are produced by the host itself,such as mucus, antibodies or digestive enzymes. In the host, the GImicrobiota serve a wide array of functions including fermentingsubstrates into short chain fatty acids (SCFAs) that are used by thehost, detoxifying undesired compounds, training the immune system,stimulating intestinal cell growth (e.g., intestinal epithelial cells),preventing growth of harmful pathogenic bacteria, regulating thedevelopment of the gut, producing vitamins for the host, such as biotinand vitamin K, producing hormones to direct the host to store fats,reducing the colonic pH, stimulating water and sodium absorption, andpromoting gastrointestinal and metabolic health in general. There areintimate interactions between the GI tract at the one hand and otherorgans in the body, such as liver, adipose tissue and brain, explainingthe large impact of GI microbiota on the health of the host. Moreover,as the GI microbiota is modulated strongly by diet, the role of the GImicrobiota in dietary conversions is of high importance. The GImicrobiota composition varies across individuals and apart from the dietis influenced by various other factors such as genes, age, and use ofantibiotics (Salonen and de Vos, Annu. Rev. Food Sci. Technol. 2014,5:239-62).

Variations in the GI microbiota may cause pathogenic species to multiplyand subsequently outnumber the beneficial bacterial species. Beneficialbacterial species are associated with an array of beneficial effects,including the production of important nutrients and vitamins, thepromotion of growth and integrity of intestinal cells, as well as thepromotion of immunity through protection against pathogenic species. Awell-studied beneficial function of intestinal bacteria is theproduction of one of the SCFAs, butyrate or butyric acid, by so-calledbutyrogenic bacteria. At the intestinal level, butyrate plays aregulatory role on the transepithelial fluid transport, amelioratesmucosal inflammation and oxidative status, reinforces the epithelialdefense barrier, and modulates visceral sensitivity and intestinalmotility. In addition, a growing number of studies have stressed therole of butyrate in the prevention and inhibition of colorectal cancer.At the systemic level, butyrate exerts potentially useful effects onmany conditions, including hemoglobinopathies and other genetic ormetabolic diseases, such as hypercholesterolemia, insulin resistance,and ischemic stroke (Canani et al., World J. Gastroenterol. 2011,17:1519-28). Only a limited number of anaerobic intestinal bacteria areknown to produce butyrate. Notably, butyrogenic bacteria are depleted inthe GI tract of patients with metabolic diseases, such as metabolicsyndrome and insulin resistance or insulin resistance-relatedcomplications, such as dyslipidemia and type 2 diabetes mellitus as wellas insulin-resistance in endocrine diseases (e.g., obese subjects withtype 1 diabetes mellitus, Cushing's disease or lipodystrophy syndromes)(Hartstra et al., Diabetes Care 2015, 38:159-165).

An excess of pathogenic bacterial species in the GI tract, which isoften associated with a reduction of butyrogenic bacteria in the GItract, has been involved in several immune-related, inflammation-relatedand other disease conditions, including cancer (e.g., colorectalcancer), inflammatory bowel disease (IBD) (e.g., Crohn's disease,ulcerative colitis), irritable bowel syndrome (IBS), type 2 diabetesmellitus, obesity, bacterial or viral diarrhea, constipation, bloating,allergies, urinary tract infections, and others.

Moreover, diet is an important driver of disease and specific componentsof the diet may contribute to diseases indirectly via GI bacteria. Thisspecifically relates to so called Advanced Glycation End products(AGEs). AGEs are formed via glycation reactions that occur through theformation of a Schiff base intermediate followed by an Amadorirearrangement to give the ketoamine adduct. When glucose is the reducingsugar, the Amadori rearrangement product is known as fructose-lysine.Spontaneous chemical conversion under slight alkaline conditions canresult in further rearrangement, fragmentation and oxidation reactionsof fructose-lysine, resulting in the formation of well-known AGEs, suchas N^(ε)-(carboxymethyl)lysine (Hellwig and Henle, Angew. Chem. Int. Ed.2014, 53:10316-10329). Thus, fructose-lysine is a pivotal product in AGEformation, the more so as glucose is among the most abundant sugars andlysine is among the most abundant amino acids on this planet.Fructose-lysine is used as an indicator for AGE formation and thefructose-lysine content can be very high in heated foods such as milkpowder, evaporated milk or some pasta products. AGEs have beenimplicated in a variety of diseases, such as metabolic syndrome, type 2diabetes mellitus, cardiovascular disease, ovarian aging, polycysticovary syndrome and neurodegenerative disorders, such as Alzheimer'sdisease, multiple sclerosis and dementia. Certain GI bacteria—but notbutyrogenic bacteria—have been implied in the metabolic conversions ofAGEs (Tuohy et al., Mol. Nutr. Food Res. 2006, 50:847-857 DOI10.1002/mnfr.200500126 847).

In the GI tract, L-lysine can be converted into toxic compounds thatpromote hepatic encephalopathy or cardiovascular diseases (Fujita etal., Clin. Chim. Acta. 1999, 287(1-2):99-109; Tang et al., J. Card.Fail. 2013, 19(4):219-224).

Several products and methods have been developed to help restore thebalance between beneficial and pathogenic bacterial species or toincrease the number of beneficial bacterial species and/or decrease thenumber of pathogenic bacterial species so as to prevent and/or treatconditions resulting from deleterious bacterial variations (e.g., excesspathogenic bacterial species and/or insufficiency of beneficialbacterial species) in the GI microbiota. Among some of the most commonlyused products dedicated to improve and/or restore GI health are theso-called “prebiotic” and “probiotic” products. Fecal microbiotatransplants have also been used, albeit less frequently, and an emergingfield is the use of synthetic communities of specific bacteria isolatedfrom the GI tract.

Probiotic products essentially consists of live microorganisms,which—when administered in effective amounts—confer a health benefit onthe host (e.g., human being). Probiotics are typically used to increasethe population of beneficial bacterial species in the gut or to helprepopulate the gut with beneficial intestinal bacteria and compensatefor deficiencies, for example, such as resulting from the use ofantibiotics, disease, aging and/or poor nutrition. While probiotics areliving microorganisms that help maintain a healthy GI, prebiotics arethe substances that help fuel the beneficial intestinal bacteria. Morespecifically, prebiotics consist mainly of fermentable fibers ornon-digestible carbohydrates that stimulate the growth and activity ofthese beneficial intestinal bacteria. The fermentation of these fibersby the beneficial bacteria promotes the production of beneficial endproducts, such as SCFAs.

Several probiotic products exist on the market in the form ofcompositions, beverages (e.g., dairy beverages, fermented beverages,etc.), formulations, food (e.g., yogurt, cheese, etc.) or nutritionalsupplements (e.g., capsules, tablets, powder, etc.), and the like. Mostprobiotics contain lactic acid bacteria, such as Lactobacilli andBifidobacteria.

There is a need for further compositions, such as probiotics, which aresuitable for maintaining, restoring and/or improving GI health ingeneral, and/or for preventing and/or treating conditions or diseasessuch as cancer (e.g., colorectal cancer), IBD (e.g., Crohn's disease,ulcerative colitis), IBS, obesity, bacterial and viral diarrhea,constipation, bloating, allergies, urinary tract infections, metabolicdiseases, such as metabolic syndrome and insulin resistance or insulinresistance-related complications, such as dyslipidemia and type 2diabetes mellitus as well as insulin-resistance in endocrine diseases(e.g., obese subjects with type 1 diabetes mellitus, Cushing's diseaseor lipodystrophy syndromes), cardiovascular disease, ovarian aging,polycystic ovary syndrome, neurodegenerative disorders, such asAlzheimer's disease, multiple sclerosis and dementia, encephalopathy, orothers. There is also a need for beneficial GI bacteria that are capableof metabolizing or degrading fructose-lysine to prevent or reduceformation of AGEs.

BRIEF SUMMARY

In a first aspect, this disclosure provides an isolated intestinalbacterial strain, i.e., a human intestinal isolate, comprising a lysinepathway gene set, the bacterium being capable of converting L-lysineinto butyric acid and/or butyrate or a derivative thereof, or a strainwhich has been derived therefrom.

In an embodiment, the lysine pathway gene set comprises one or more ofthe genes encoding the proteins: Lysine 2,3-aminomutase; L-beta-lysine5,6-aminomutase alpha subunit; L-beta-lysine 5,6-aminomutase betasubunit; 3,5-diaminobexanoate dehydrogenase; 3-keto-5-aminohexanoatecleavage enzyme; 3-aminobutyryl-CoA ammonia-lyase; butyrate-acetoacetateCoA-transferase subunit A; butyrate-acetoacetate CoA-transferase subunitB; acetyl-CoA:acetoacetyl-CoA transferase.

In an embodiment, the expression of at least one of the genes encodingthe proteins: Lysine 2,3-aminomutase; L-beta-lysine 5,6-aminomutasealpha subunit; L-beta-lysine 5,6-aminomutase beta subunit;3,5-diaminobexanoate dehydrogenase; 3-keto-5-aminohexanoate cleavageenzyme; 3-aminobutyryl-CoA ammonia-lyase; butyrate-acetoacetateCoA-transferase subunit A; butyrate-acetoacetate CoA-transferase subunitB; acetyl-CoA:acetoacetyl-CoA transferase, is upregulated when thebacterium is grown on L-lysine as the sole carbon source as compared towhen the bacterium is grown on equimolar amounts of glucose and acetateas the sole carbon source.

In an embodiment, at least one of the proteins: Lysine 2,3-aminomutase;L-beta-lysine 5,6-aminomutase alpha subunit; L-beta-lysine5,6-aminomutase beta subunit; 3,5-diaminobexanoate dehydrogenase;3-keto-5-aminohexanoate cleavage enzyme; 3-aminobutyryl-CoAammonia-lyase; butyrate-acetoacetate CoA-transferase subunit A;butyrate-acetoacetate CoA-transferase subunit B;acetyl-CoA:acetoacetyl-CoA transferase, is overexpressed when thebacterium is grown on L-lysine as the sole carbon source as compared towhen the bacterium is grown on equimolar amounts of glucose and acetateas the sole carbon source.

The disclosure also pertains to an isolated intestinal bacterial straindeposited as CBS 139326 or a strain that has been derived therefrom. Thebacterial strain may be capable of converting L-lysine into butyric acidand/or butyrate or a derivative thereof. The bacterial strain may becapable of converting L-lysine into butyric acid and/or butyrate or aderivative thereof and acetate or a derivative thereof.

The bacterial strain taught herein may further comprise a glycatedlysine uptake and degradation operon, and may be capable of convertingglycated lysine into butyric acid and/or butyrate or a derivativethereof.

The glycated lysine may be fructose-lysine, and the glycated lysineuptake and degradation operon may be a fructose-lysine uptake anddegradation operon.

In an embodiment, the fructose-lysine uptake and degradation operoncomprises one or more of the genes encoding the proteins:fructose-lysine kinase; fructose-lysine 3-epimerase; fructosaminedeglycase; ABC transporter periplasmic spermidine putrescine-bindingprotein PotD; spermidine putrescine ABC transporter permease componentPotC; spermidine putrescine ABC transporter permease component PotB; andputrescine transport ATP-binding protein PotA.

In an embodiment, the expression of at least one of the genes encodingthe proteins: fructose-lysine kinase; fructoselysine 3-epimerase;fructosamine deglycase; ABC transporter periplasmic spermidineputrescine-binding protein PotD; spermidine putrescine ABC transporterpermease component PotC; spermidine putrescine ABC transporter permeasecomponent PotB; and putrescine transport ATP-binding protein PotA, isupregulated when the bacterium is grown on L-lysine as the sole carbonsource as compared to when the bacterium is grown on equimolar amountsof glucose and acetate as the sole carbon source.

In an embodiment, at least one of the proteins: fructose-lysine kinase;fructoselysine 3-epimerase; fructosamine deglycase; ABC transporterperiplasmic spermidine putrescine-binding protein PotD; spermidineputrescine ABC transporter permease component PotC; spermidineputrescine ABC transporter permease component PotB; and putrescinetransport ATP-binding protein PotA, is overexpressed when the bacteriumis grown on L-lysine as the sole carbon source as compared to when thebacterium is grown on equimolar amounts of glucose and acetate as thesole carbon source.

The bacterial strain taught herein may belong to the phylum Firmicutes,the taxon Clostridium cluster IV, the genus Intestinimonas, andpreferably belongs to the species Intestinimonas butyriciproducens.

In an embodiment, the bacterial strain taught herein is isolated from ahuman intestine, i.e., is a human intestinal isolate.

Preferably, the human intestinal isolate has an MIC of erythromycin ofless than 20 μg/ml, more preferably less than 15 μg/ml, yet morepreferably less than 10 μg/ml, yet more preferably less than 7 μg/ml,even more preferably less than 5 μg/ml, most preferably less than 4,less than 3, or less than 2 μg/ml.

The disclosure further relates to a composition comprising a bacterialstrain as taught herein and a physiologically acceptable carrier. Thecomposition may be a food, food supplement, feed, feed supplement, orpharmaceutical composition.

In an embodiment, the composition taught herein is a food composition,such as a dairy product, e.g., a fermented dairy product, such as ayogurt or a yogurt drink.

In an embodiment, the composition taught herein is a pharmaceuticalcomposition or a food supplement composition. The composition may be insolid dosage form, e.g., may be a capsule, a tablet, or a powder. Thebacteria belonging to the bacterial strain taught herein may beincorporated into the composition in lyophilized form.

The bacterium may be present in the composition in an amount of about10² to about 10¹², preferably 10⁶ to about 10¹⁰, colony forming units(CFU).

The composition may further comprise ingredients selected from the groupconsisting of prebiotics, probiotics, carbohydrates, polypeptides,lipids, vitamins, minerals, medicinal agents, preservative agents, orany combination thereof.

The composition may further comprise a lysine-rich source.

The disclosure also pertains to a bacterial strain as taught herein foruse as a medicament, as well as to a composition as taught herein foruse as a medicament.

Additionally, the disclosure relates to a bacterial strain as taughtherein for use as a probiotic and/or symbiotic, as well as to acomposition as taught herein for use as a probiotic and/or symbiotic.

In another aspect, this disclosure is concerned with a bacterial strainas taught herein or a composition as taught herein for use inmaintaining, restoring and/or improving GI health in general, and/or forpreventing and/or treating conditions or diseases such as cancer (e.g.,colorectal cancer), IBD (e.g., Crohn's disease, ulcerative colitis),IBS, obesity, bacterial and viral diarrhea, constipation, bloating,allergies, urinary tract infections, metabolic diseases, such asmetabolic syndrome and insulin resistance or insulin resistance-relatedcomplications, such as dyslipidemia and type 2 diabetes mellitus as wellas insulin-resistance in endocrine diseases (e.g., obese subjects withtype 1 diabetes mellitus, Cushing's disease or lipodystrophy syndromes),cardiovascular disease, ovarian aging, polycystic ovary syndrome,neurodegenerative disorders, such as Alzheimer's disease, multiplesclerosis and dementia, or encephalopathy.

In a further aspect, this disclosure provides for a method formaintaining, restoring and/or improving GI health in general, and/or forpreventing and/or treating conditions or diseases such as cancer (e.g.,colorectal cancer), IBD (e.g., Crohn's disease, ulcerative colitis),IBS, obesity, bacterial and viral diarrhea, constipation, bloating,allergies, urinary tract infections, metabolic diseases, such asmetabolic syndrome and insulin resistance or insulin resistance-relatedcomplications, such as dyslipidemia and type 2 diabetes mellitus as wellas insulin-resistance in endocrine diseases (e.g., obese subjects withtype 1 diabetes mellitus, Cushing's disease or lipodystrophy syndromes),cardiovascular disease, ovarian aging, polycystic ovary syndrome,neurodegenerative disorders, such as Alzheimer's disease, multiplesclerosis and dementia, or encephalopathy in a subject in need thereof,the method comprising the step of increasing the level of a bacterialstrain as taught herein in the subject.

In an embodiment, the level of the bacterial strain as taught herein maybe increased in the subject by a method selected from the groupconsisting of administering an effective amount of the bacterial strainto the subject, and administering an effective amount of a compoundcapable of increasing the level of the bacterial strain in the subject.

In yet another aspect, the disclosure pertains to a method forpreventing and/or reducing the production of glycated lysine in asubject comprising the step of increasing the level of a bacterialstrain as taught herein in the subject.

In an embodiment, the level of the bacterial strain as taught herein maybe increased in the subject by a method selected from the groupconsisting of administering an effective amount of the bacterial strainto the subject, and administering an effective amount of a compoundcapable of increasing the level of the bacterial strain in the subject.

Preferably, the subject is a mammal, even more preferably a human being.

General Definitions

The term “probiotics” or “probiotic products” as used herein refers tomicroorganisms such as intestinal bacteria, which—when administered oringested in effective amounts—confer health benefits to the host (e.g.,humans or mammals). Preferably, probiotics should be alive or viablewhen administered to a subject so as to allow the probiotics to colonizethe large intestine of the host. However, under certain conditions,probiotics may also be dead when administered provided that substancesproduced by the probiotics still exert probiotic, beneficial effects onthe host. Most probiotics or probiotic products are composed of lacticacid bacteria such as Lactobacilli or Bifidobacteria. The skilled personis well-acquainted with the field of probiotics and knows how to selectlactic acid bacteria endowed with probiotic activity.

The term “prebiotics” or “prebiotic products” as used herein generallyrefers to compounds that promote the growth and/or activity of GImicroorganisms that contribute to the well-being of their host.Prebiotics or prebiotic products consist mainly of fermentable fibers ornon-digestible carbohydrates. The fermentation of these fibers byprobiotics promotes the production of beneficial end products, such asSCFAs, particularly butyrates. The skilled person is well-acquaintedwith the field of prebiotics and knows how to select ingredients endowedwith prebiotic activity.

The term “symbiotics” or “symbiotic products” as used herein generallyrefers to compositions and/or nutritional supplements combiningprobiotics and one or more compounds that promote the growth and/oractivity of GI microorganisms, such as prebiotics, into one product. Thesymbiotic beneficially affects the host by improving the survival andcolonization of the probiotic in the GI tract, by selectivelystimulating the growth and/or by activating the metabolism of theprobiotic, thus improving host welfare. The skilled person iswell-acquainted with symbiotics and knows how to select ingredients thatmay be combined into a symbiotic.

The term “short chain fatty acids” (abbreviated as “SCFAs”) as usedherein refers to fatty acids with aliphatic tails of up to six carbons,including formic acid, acetic acid, propionic acid butyric acid andvaleric acid (pentanoic acid), while branched chain fatty acids (BCFAs)include isobutyric acid (2-methylpropanoic acid) and isovaleric acid(3-methylbutanoic acid), and the like. SCFAs may be produced whendietary fibers are fermented in the lower intestine of mammals whileBCFAs are predominantly formed from protein fermentation. Specifically,the production of the SCFAs acetic acid, propionic acid and butyric acidin the lower intestine of mammals is the result of fermentation ofdietary carbohydrates.

The term “butyric acid” (also known under the systematic name butanoicacid) as used herein refers to a carboxylic acid with the structuralformula CH₃CH₂CH₂COOH. The term “butyric acid or a derivative thereof”as used herein refers to compounds derived from butyric acid andincludes salts and esters of butyric acid, which are known as butyratesor butanoates. Non-limiting examples of butyrate salts include sodiumbutyrate, calcium butyrate, magnesium butyrate, manganese butyrate,cobalt butyrate, barium butyrate, lithium butyrate, zinc butyrate,potassium butyrate, ferrous butyrate and the like. Non-limiting examplesof butyrate esters (i.e., esters of butyric acid) include celluloseacetate butyrate, methyl butyrate, ethyl butyrate, butyl butyrate,pentyl butyrate, and the like.

The terms “butyrate-producing bacterium” or “butyric acid-producingbacterium” or “butyrogenic bacterium” are used interchangeably hereinand refer to a bacterium which is capable of producing butyric acidand/or butyrate and/or one or more derivatives thereof. A prominentpathway by which butyric acid and/or butyrate and derivative thereof maybe produced in situ in the mammalian gut (or in vitro in culture) is theso-called “acetyl-CoA pathway.” The acetyl-CoA pathway has beenwell-documented and is known to be particularly prevalent in intestinalbacteria belonging, for instance, to the genus Lachnospiraceae andRuminococcaceae (which together may form up to 20% of total gutmicrobiota). According to the acetyl-CoA pathway, butyric acid and/orbutyrate and/or derivatives thereof may be formed by a single bacterialspecies via carbohydrate fermentation and/or by a group ofmicroorganisms where metabolites from other organisms act as a substratefor butyrogenic bacteria. The conventional acetyl-CoA pathway involves acascade of enzymes, including (among many others) two key enzymesreferred to as butyryl-CoA transferase (But) and butyrate kinase (Buk).The skilled person is well-acquainted with the acetyl-CoA pathwayincluding genes coding for enzymes and other elements underlying thefunctioning of the pathway as well as intestinal bacterial species thathave this pathway.

It has been hypothesized that other pathways by which butyric acidand/or butyrate and/or derivatives thereof may be produced in the humanGI may exist. One of such pathways is the so-called “lysine utilizationpathway” or “lysine pathway.” However, this pathway has not beenreported to exist in bacterial species isolated from the human GI (Vitalet al., 2014, mBio 5(2) doi:10.1128/mBio.00889-14).

The term “lysine pathway gene set” as used herein refers to a set ofgenes that encode proteins involved in the lysine pathway for conversionof L-Lysine into butyric acid and/or butyrates or a derivative thereof.In an embodiment of this disclosure, the lysine pathway gene setcomprises genes encoding the proteins: Lysine 2,3-aminomutase;L-beta-lysine 5,6-aminomutase alpha subunit; L-beta-lysine5,6-aminomutase beta subunit; 3,5-diaminobexanoate dehydrogenase;3-keto-5-aminohexanoate cleavage enzyme; 3-aminobutyryl-CoAammonia-lyase; butyrate-acetoacetate CoA-transferase subunit A;butyrate-acetoacetate CoA-transferase subunit B;acetyl-CoA:acetoacetyl-CoA transferase. The lysine pathway gene set mayfurther comprise one or more genes encoding the proteins: L-Lysinepermease; butyryl-CoA dehydrogenase Etf; 4-hydroxybutyrate coenzyme Atransferase; 3-ketoacyl-CoA thiolase/acetyl-CoA acetyltransferase;phosphate acetyltransferase; acetate kinase; proton pumping Rnf cluster(A, B, C, D, E, G subunits); V-type ATP synthase cluster (A, B, C, D, E,F, I, K subunits); inorganic pyrophosphatase; ammonium transporter;putative short chain fatty acids transporter; and Na+/H+ antiporter.

In an embodiment of this disclosure, the lysine pathway gene set mayfurther comprise one or more genes encoding the proteins:3-hydroxybutyryl-CoA dehydratase; D-beta-hydroxybutyrate permease;electron transfer flavoprotein alpha subunit; electron transferflavoprotein beta subunit; NAD-reducing hydrogenase subunit HoxE;ferredoxin; NAD-reducing hydrogenase subunit HoxF; periplasmic [Fe]hydrogenase large subunit; and Substrate-specific component RibU ofriboflavin ECF transporter.

The term “lysine” as used in the context of this disclosureadvantageously refers to “L-lysine,” and can be used interchangeably.

The term “fructose-lysine uptake and degradation operon” or “glycatedlysine uptake and degradation operon” as used herein refers to a set ofgenes involved in the fructose-lysine uptake and degradation pathway forconverting fructose-lysine into butyric acid and/or butyrate or aderivate thereof.

In an embodiment, the “fructose-lysine uptake and degradation operon”comprises genes coding for the proteins: fructose-lysine kinase;fructose-lysine 3-epimerase; fructosamine deglycase; and an ABCtransporter consisting of 4 subunits, the periplasmic spermidineputrescine-binding protein PotD, the spermidine putrescine ABCtransporter permease component PotC, the spermidine putrescine ABCtransporter permease component PotB, and the putrescine transportATP-binding protein PotA.

The term “beneficial intestinal bacteria species” as used herein refersto a bacterium species that inhabits (i.e., is innate) the mammalian(e.g., human) intestine and exerts beneficial effect(s) (e.g.,protection against pathogenic bacteria species, production of butyricacid and/or butyrate and derivatives, etc.) on the GI, metabolic andother health of a mammal in which it resides.

Non-limiting examples of beneficial intestinal bacterial species includelactic acid bacteria from the genera Lactobacillus and Bifidobacterium.Other non-limiting examples of beneficial intestinal bacterial speciesinclude butyrate-producing bacterial species, which use the acetyl-CoAto produce butyric acid and/or butyrate and derivatives thereof, such asthe bacterial strains disclosed in US 2014/0242654, WO 2014/150094 or WO2013032328 A1.

The term “pathogenic bacterial species” as used herein refers to abacterium that inhabits (i.e., is innate) the mammalian (e.g., human)intestine and exerts deleterious effect(s) (e.g., infection) on the GIhealth of a mammal in which it resides. A notorious non-limiting exampleof a pathogenic bacterial species is the toxin-producing Clostridiumdifficile.

The term “glycated lysine” or “Amadori glycated lysine” or“fructose-lysine” as used herein refers to a product comprising a lysinein which a lysine epsilon NH₂ group is glycated by means of an Amadorirearrangement. The skilled person is well-acquainted with the process bywhich Amadori glycated lysine or fructose-lysine are formed. The termfructose-lysine is employed when a glucose moiety is covalently coupledto a lysine via an Amadori arrangement. Fructose-lysine is also known asε-fructose-lysine, 1-Deoxy-1-(ε-N-L-lysino)-D-fructose; fructosyllysine;Nε-(1-Deoxy-D-fructos-1-yl)-L-lysine;D-1-[(L-5-Amino-5-carboxypentyl)amino]-1-deoxyfructose; or(S)-1-[(5-Amino-5-carboxypentyl)amino]-1-deoxy-D-Fructose.

Amadori glycated lysine and fructose-lysine are abundant in cookedfoods. Amadori glycated lysine or fructose-lysine are typically formedvia non-enzymatic reaction of glucose and amino acids upon the foodheating process. Spontaneous chemical conversion under slight alkalineconditions can result in further rearrangement, fragmentation andoxidation reactions of FL, resulting in the formation of well-knownAGEs, such as N^(ε)-(carboxymethyl)lysine. AGEs have been implicated ina variety of diseases, such as metabolic syndrome, type 2 diabetesmellitus, cardiovascular disease, ovarian aging, polycystic ovarysyndrome and neurodegenerative disorders, such as Alzheimer's disease,multiple sclerosis and dementia.

The term “effective amount” as used herein refers to an amount necessaryto achieve an effect as taught herein. For instance, an effective amountof the intestinal bacterial strain or a strain derived therefrom astaught herein is an amount which is effectively useful for maintaining,restoring, and/or improving GI heath in a human being, for convertingAmadori glycated lysine or fructose-lysine into butyric acid and/orbutyrate or a derivative thereof and/or for preventing and/or treatingconditions or diseases described herein, which are related to thepresence of lysine, the absence or reduction of butyrogenic GI bacteria,or to the presence of AGEs, in a subject, preferably a human being.These conditions or diseases include, without limitation, cancer (e.g.,colorectal cancer), IBD (e.g., Crohn's disease, ulcerative colitis),IBS, obesity, bacterial and viral diarrhea, constipation, bloating,allergies, urinary tract infections, metabolic diseases, such asmetabolic syndrome and insulin resistance or insulin resistance-relatedcomplications, such as dyslipidemia and type 2 diabetes mellitus as wellas insulin-resistance in endocrine diseases (e.g., obese subjects withtype 1 diabetes mellitus, Cushing's disease or lipodystrophy syndromes),cardiovascular disease, ovarian aging, polycystic ovary syndrome,neurodegenerative disorders, such as Alzheimer's disease, multiplesclerosis and dementia, or encephalopathy. The effective amount can bereadily determined without undue experimentation by a person of ordinaryskill in the art.

The term “a strain that derives therefrom” as used herein relates tostrains obtained by using the deposited strain as taught herein asstarting material. The strain that derives therefrom may be a mutantstrain, which may be derived from a strain of the disclosure by meansof, for instance, genetic engineering, radiation, UV light, chemicaltreatment. Alternatively, such derivative or mutant strain may be astrain derived from the deposited strain as taught herein that has beensubjected to growth adaptation to particular conditions resulting in anadditional benefit to the derivative strain, such as more rapid growth,better survival in the gut, enhanced lysine to butyrate conversionand/or enhanced glycated lysine, e.g., fructose-lysine, to butyrateconversion due to adaptation to growth on lysine and/or glycated lysine,e.g., fructose-lysine, and the like, using methods that are well-knownto the skilled person. It is preferred that the derivative or mutant isfunctionally equivalent to the deposited strain as taught herein. Apreferred derivative or mutant as taught herein has substantially thesame activity or function as the deposited strain as taught herein,i.e., has the ability to convert L-lysine into butyric acid and/orbutyrate and derivatives and/or has the ability to convert glycatedlysine, e.g., fructose-lysine, into butyric acid and/or butyrate or aderivative thereof. The derivative or mutant advantageously providessubstantially the same benefits to a mammal (e.g., humans or othermammals) administered with the derivative or mutant as would be the caseupon administration of the deposited strain. The derivative or mutantstrain may also be a spontaneous derivative or mutant strain having thesame characteristics as described herein for the deposited strain.

The term “suitable for consumption” or “nutritionally acceptable” refersto ingredients or substances, which are generally regarded as safe forhuman (as well as other mammals) consumption.

“Minimum inhibitory concentration” or “MIC” as used herein refers to thelowest concentration of an antimicrobial that will inhibit the visiblegrowth of a microorganism after overnight incubation. Minimum inhibitoryconcentrations are important in diagnostic laboratories to confirmresistance of microorganisms to an antimicrobial agent and also tomonitor the activity of new antimicrobial agents. An MIC is generallyregarded as the most basic laboratory measurement of the activity of anantimicrobial agent against an organism.

The term “about,” as used herein, indicates a range of normal tolerancein the art, for example within two standard deviations of the mean. Theterm “about” can be understood as encompassing values that deviate atmost 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or0.01% of the indicated value.

The terms “comprising” or “to comprise” and their conjugations, as usedherein, refer to a situation wherein the terms are used in theirnon-limiting sense to mean that items following the word are included,but items not specifically mentioned are not excluded. It alsoencompasses the more limiting verb “to consist essentially of” and “toconsist of.”

Reference to an element by the indefinite article “a” or “an” does notexclude the possibility that more than one of the elements is present,unless the context clearly requires that there be one and only one ofthe elements. The indefinite article “a” or “an” thus usually means “atleast one.”

The terms “to increase” and “increased level” and the terms “todecrease” and “decreased level” refer to the ability to significantlyincrease or significantly decrease or to a significantly increased levelor significantly decreased level. Generally, a level is increased ordecreased when it is at least 5%, such as 10%, 15%, 20%, 25%, 30%, 35%,40%, 45%, 50% higher or lower, respectively, than the correspondinglevel in a control or reference. Alternatively, a level in a sample maybe increased or decreased when it is statistically significantlyincreased or decreased compared to a level in a control or reference.

DETAILED DESCRIPTION

The present inventors have isolated for the first time a new intestinalbacterial strain from the human GI tract, which is referred to herein asIntestinimonas AF211. Specifically, the new intestinal bacterial strainis a butyric acid and/or butyrate-producing (butyrogenic) bacterium,which is capable of converting L-lysine into butyric acid and/orbutyrate or a derivative thereof via the so-called “lysine utilizationpathway.” The new intestinal bacterial strain of the disclosure isfurther capable of converting a glycated lysine or other AGEs, e.g.,fructose-lysine, into butyric acid and/or butyrate or a derivativethereof via the so-called “fructose-lysine uptake and degradationpathway.”

Without wishing to be bound to any theories, it is believed that thenovel intestinal bacterial strain (or strains derived therefrom) taughtherein, when administered to a human being or when ingested by a humanbeing in an adequate amount, is able to colonize the GI tract of thehuman being. This colonization enables greater in situ production ofbutyric acid and/or butyrate or a derivative thereof as well as greatermetabolism of fructose-lysine or other glycated lysine in the GI tractof the human being. Increased in situ production of butyric acid and/orbutyrate or a derivative thereof and/or increased metabolism offructose-lysine in the GI tract is believed to underlie the beneficialeffects as taught herein, e.g., maintaining, restoring and/or improvingGI health in general, and/or preventing and/or treating conditions ordiseases such as cancer (e.g., colorectal cancer), IBD (e.g., Crohn'sdisease, ulcerative colitis), IBS, obesity, bacterial and viraldiarrhea, constipation, bloating, allergies, urinary tract infections,metabolic diseases, such as metabolic syndrome and insulin resistance orinsulin resistance-related complications, such as dyslipidemia and type2 diabetes mellitus as well as insulin-resistance in endocrine diseases(e.g., obese subjects with type 1 diabetes mellitus, Cushing's diseaseor lipodystrophy syndromes), cardiovascular disease, ovarian aging,polycystic ovary syndrome and neurodegenerative disorders, such asAlzheimer's disease, multiple sclerosis and dementia, or others.

Bacterium

In a first aspect, this disclosure relates to a bacterial strain, or astrain derived therefrom, that comprises a lysine pathway gene set andis capable of converting L-lysine into butyric acid and/or butyrate or aderivative thereof. The bacterial strain is preferably a human intestineisolate.

In a second aspect, this disclosure relates to a bacterial straindeposited by Wageningen University on Jan. 5, 2015 at the Centraalbureauvoor Schimmelcultures located in Utrecht, the Netherlands, assigned thedeposit number CBS 139326.

In an embodiment, the isolated bacterium as taught herein may be furthercapable of converting L-Lysine into butyric acid and/or butyrate or aderivative thereof and acetate or a derivative thereof. Acetate isthought to reduce the appetite and may therefore be useful for weightloss purposes, e.g., for treating and/or preventing obesity.

In an embodiment, the intestinal bacterial strain as taught herein maybe capable of converting L-lysine into butyric acid and/or butyrate or aderivative thereof from any protein sources comprising lysine.Non-limiting examples of protein sources comprising lysine includetryptic soy broth without dextrose, trypton, casiton, vegetable peptone,yeast extract, bacterial peptone, casein hydrolysate, methyllysine, andthe like.

In an embodiment, the lysine pathway gene set may comprise one or moreof the genes encoding the proteins: lysine 2,3-aminomutase;L-beta-lysine 5,6-aminomutase alpha subunit; L-beta-lysine5,6-aminomutase beta subunit; 3,5-diaminobexanoate dehydrogenase;3-keto-5-aminohexanoate cleavage enzyme; 3-aminobutyryl-CoAammonia-lyase; butyrate-acetoacetate CoA-transferase subunit A;butyrate-acetoacetate CoA-transferase subunit B;acetyl-CoA:acetoacetyl-CoA transferase. Alternatively, the lysinepathway gene set may comprises at least two, three, four, five, six,seven, eight or all nine of the genes encoding the proteins: lysine2,3-aminomutase; L-beta-lysine 5,6-aminomutase alpha subunit;L-beta-lysine 5,6-aminomutase beta subunit; 3,5-diaminobexanoatedehydrogenase; 3-keto-5-aminohexanoate cleavage enzyme;3-aminobutyryl-CoA ammonia-lyase; butyrate-acetoacetate CoA-transferasesubunit A; butyrate-acetoacetate CoA-transferase subunit B;acetyl-CoA:acetoacetyl-CoA transferase.

The lysine pathway gene set may further comprise one or more of thegenes encoding the proteins: L-Lysine permease; butyryl-CoAdehydrogenase Etf; 4-hydroxybutyrate coenzyme A transferase;3-ketoacyl-CoA thiolase/acetyl-CoA acetyltransferase; phosphateacetyltransferase; acetate kinase; proton pumping Rnf cluster (A, B, C,D, E, G subunits); V-type ATP synthase cluster (A, B, C, D, E, F, I, Ksubunits); inorganic pyrophosphatase; ammonium transporter; putativeshort chain fatty acids transporter; and Na+/H+ antiporter.Additionally, the “lysine pathway gene set” may further comprise one ormore genes encoding the proteins: 3-hydroxybutyryl-CoA dehydratase;D-beta-hydroxybutyrate permease; electron transfer flavoprotein alphasubunit; electron transfer flavoprotein beta subunit; NAD-reducinghydrogenase subunit HoxE; ferredoxin; NAD-reducing hydrogenase subunitHoxF; periplasmic [Fe] hydrogenase large subunit; and Substrate-specificcomponent RibU of riboflavin ECF transporter. In an embodiment, theexpression of one or more genes encoding proteins: lysine2,3-aminomutase; L-beta-lysine 5,6-aminomutase alpha subunit;L-beta-lysine 5,6-aminomutase beta subunit; 3,5-diaminobexanoatedehydrogenase; 3-keto-5-aminohexanoate cleavage enzyme;3-aminobutyryl-CoA ammonia-lyase; butyrate-acetoacetate CoA-transferasesubunit A; butyrate-acetoacetate CoA-transferase subunit B;acetyl-CoA:acetoacetyl-CoA transferase, may be upregulated when thebacterium is grown on L-lysine as the sole carbon source as compared towhen the bacterium is grown on equimolar amounts of glucose and acetateas the sole carbon source.

In an embodiment, at least one of the proteins: lysine 2,3-aminomutase;L-beta-lysine 5,6-aminomutase alpha subunit; L-beta-lysine5,6-aminomutase beta subunit; 3,5-diaminobexanoate dehydrogenase;3-keto-5-aminohexanoate cleavage enzyme; 3-aminobutyryl-CoAammonia-lyase; butyrate-acetoacetate CoA-transferase subunit A;butyrate-acetoacetate CoA-transferase subunit B;acetyl-CoA:acetoacetyl-CoA transferase, may be overexpressed when thebacterium is grown on L-lysine as the sole carbon source as compared towhen the bacterium is grown on equimolar amounts of glucose and acetateas the sole carbon source.

In the context of this disclosure, the amount of L-lysine used todetermine whether genes are upregulated or proteins are overexpressed ina bacterial strain as compared to when the bacterium is grown onequimolar amounts of glucose and acetate may be in the range of fromabout 5 mM to about 100 mM, preferably from about 10 mM to about 50 mM,more preferably from about 15 mM to about 25 mM, and is most preferablyabout 20 mM (particularly when the comparative experiments of thebacterial strain being grown on equimolar amounts of glucose and acetateas the sole carbon source is carried out in 40 mM glucose and 40 mMacetate).

In the context of this disclosure, the equimolar amounts of glucose andacetate referred to herein may be in the range of from about 1 mM toabout 200 mM of both glucose and acetate, which may be provided in theform of an acetate salt such as sodium acetate, preferably from about 5mM to about 150 mM of both glucose and acetate, more preferably formabout 10 mM to about 100 mM of both glucose and acetate, even morepreferably from about 15 mM to about 75 mM of both glucose and acetate,yet more preferably from about 20 mM to about 60 mM of both glucose andacetate, such as from about 25 mM to about 55 mM of both glucose andacetate, from about 30 mM to about 50 mM of both glucose and acetate,from about 35 mM to about 50 mM of both glucose and acetate, preferablyabout 40 mM of both glucose and acetate.

In an embodiment, the isolated intestinal bacterial strain, or a strainderived therefrom as taught herein further comprises a glycated lysineuptake and degradation operon.

In an embodiment, the isolated intestinal bacterial strain, or strainderived therefrom, as taught herein is further capable of converting aglycated lysine into butyric acid and/or butyrate or a derivativethereof.

In an embodiment, the glycated lysine is fructose-lysine and theglycated lysine uptake and degradation operon is a fructose-lysineuptake and degradation operon.

In an embodiment, the fructose-lysine uptake and degradation operoncomprises one or more of the genes encoding the proteins:fructose-lysine kinase; fructoselysine 3-epimerase; fructosaminedeglycase; and the ABC transporter consisting of the 4 subunits: ABCtransporter periplasmic spermidine putrescine-binding protein PotD;spermidine putrescine ABC transporter permease component PotC;spermidine putrescine ABC transporter permease component PotB; andputrescine transport ATP-binding protein PotA. For example, thefructose-lysine uptake and degradation operon may comprise at least two,three, four, five, six or all seven of the genes encoding the proteins:fructose-lysine kinase; fructoselysine 3-epimerase; fructosaminedeglycase; and the ABC transporter consisting of the 4 subunits: ABCtransporter periplasmic spermidine putrescine-binding protein PotD;spermidine putrescine ABC transporter permease component PotC;spermidine putrescine ABC transporter permease component PotB; andputrescine transport ATP-binding protein PotA.

In an embodiment, the expression of at least one of the genes encodingthe proteins: fructose-lysine kinase; fructoselysine 3-epimerase;fructosamine deglycase; ABC transporter periplasmic spermidineputrescine-binding protein PotD; spermidine putrescine ABC transporterpermease component PotC; spermidine putrescine ABC transporter permeasecomponent PotB; and putrescine transport ATP-binding protein PotA, isupregulated when the bacterium is grown on L-lysine as the sole carbonsource as compared to when the bacterium is grown on equimolar amountsof glucose and acetate as the sole carbon source.

In another embodiment, at least one of the proteins: fructose-lysinekinase; fructoselysine 3-epimerase; fructosamine deglycase; ABCtransporter periplasmic spermidine putrescine-binding protein PotD;spermidine putrescine ABC transporter permease component PotC;spermidine putrescine ABC transporter permease component PotB; andputrescine transport ATP-binding protein PotA, is overexpressed when thebacterium is grown on L-lysine as the sole carbon source as compared towhen the bacterium is grown on equimolar amounts of glucose and acetateas the sole carbon source.

In the context of this disclosure, the amount of L-lysine used todetermine whether genes are upregulated or proteins are overexpressed ina bacterial strain as compared to when the bacterium is grown onequimolar amounts of glucose and acetate may be in the range of fromabout 5 mM to about 100 mM, preferably from about 10 mM to about 50 mM,more preferably from about 15 mM to about 25 mM, and is most preferablyabout 20 mM (particularly when the comparative experiments of thebacterial strain being grown on equimolar amounts of glucose and acetateas the sole carbon source is carried out in 40 mM glucose and 40 mMacetate).

In the context of this disclosure, the equimolar amounts of glucose andacetate referred to herein may be in the range of from about 1 mM toabout 200 mM of both glucose and acetate, which may be provided in theform of an acetate salt such as sodium acetate, preferably from about 5mM to about 150 mM of both glucose and acetate, more preferably formabout 10 mM to about 100 mM of both glucose and acetate, even morepreferably from about 15 mM to about 75 mM of both glucose and acetate,yet more preferably from about 20 mM to about 60 mM of both glucose andacetate, such as from about 25 mM to about 55 mM of both glucose andacetate, from about 30 mM to about 50 mM of both glucose and acetate,from about 35 mM to about 50 mM of both glucose and acetate, preferablyabout 40 mM of both glucose and acetate.

In an embodiment, the isolated human intestinal bacterial strain, orstrain derived therefrom, as taught herein comprises the lysine pathwaygene set as taught herein and/or the fructose-lysine uptake anddegradation operon as taught herein.

In a preferred embodiment, the isolated human intestinal bacterialstrain, or strain derived therefrom, as taught herein comprises both thelysine pathway gene set as taught herein and the fructose-lysine uptakeand degradation operon as taught herein.

In an embodiment, the isolated intestinal bacterial strain, or strainderived therefrom, as taught herein is an intestinal bacterium isolatedfrom a human being, which naturally comprises a lysine pathway gene setand/or a fructose-lysine uptake and degradation operon as taught hereinand which is capable of converting L-lysine into butyric acid and/orbutyrate or a derivative thereof and/or is capable of convertingfructose-lysine into butyric acid and/or butyrate or a derivativethereof.

In another embodiment, the bacterial strain as taught herein is abacterial strain, which has been transfected with the lysine pathwaygene set and/or the fructose-lysine uptake and degradation operon astaught herein, and which is capable of converting L-lysine into butyricacid and/or butyrate or a derivative thereof and/or is capable ofconverting fructose-lysine into butyric acid and/or butyrate or aderivative thereof. The skilled person is well-acquainted with methodsfor transfecting bacteria with a desired genetic construct (e.g., operonor pathway gene set).

Preferably, the human intestinal isolate taught herein is sensitive toerythromycin, having an MIC of erythromycin of less than 20 μg/ml, morepreferably less than 15 μg/ml, yet more preferably less than 10 μg/ml,yet more preferably less than 7 μg/ml, even more preferably less than 5μg/ml, most preferably less than 4, less than 3, or less than 2 μg/ml.This allows the isolate to be administered to human beings withoutintroducing erythromycin-resistant bacteria.

In an embodiment, the human intestinal isolate taught herein issensitive to cefotaxime, having an MIC of cefotaxime of less than 20μg/ml, more preferably less than 15 μg/ml, yet more preferably less than10 μg/ml, yet more preferably less than 7 μg/ml, even more preferablyless than 5 μg/ml, most preferably less than 4, less than 3, or lessthan 2 μg/ml, even more preferably less than 1 μg/ml. This allows theisolate to be administered to human beings without introducingcefotaxime-resistant bacteria.

In an embodiment, the human intestinal isolate taught herein issensitive to oxacillin, having an MIC of oxacillin of less than 20μg/ml, more preferably less than 15 μg/ml, yet more preferably less than10 μg/ml, yet more preferably less than 7 μg/ml, even more preferablyless than 5 μg/ml, most preferably less than 4, less than 3, or lessthan 2 μg/ml, even more preferably less than 1 μg/ml. This allows theisolate to be administered to human beings without introducingoxacillin-resistant bacteria.

In an embodiment, the human intestinal isolate taught herein issensitive to teicoplanin, having an MIC of teicoplanin of less than 20μg/ml, more preferably less than 15 μg/ml, yet more preferably less than10 μg/ml, yet more preferably less than 7 μg/ml, even more preferablyless than 5 μg/ml, most preferably less than 4, less than 3, or lessthan 2 μg/ml, even more preferably less than 1 μg/ml. This allows theisolate to be administered to human beings without introducingteicoplanin-resistant bacteria.

In an embodiment, the human intestinal isolate taught herein issensitive to tobramycin, having an MIC of tobramycin of less than 20μg/ml, more preferably less than 15 μg/ml, yet more preferably less than10 μg/ml, yet more preferably less than 7 μg/ml, even more preferablyless than 5 μg/ml, most preferably less than 4, or less than 3. Thisallows the isolate to be administered to human beings withoutintroducing tobramycin-resistant bacteria.

In an embodiment, the human intestinal isolate taught herein issensitive to vancomycin, having an MIC of vancomycin of less than 20μg/ml, more preferably less than 15 μg/ml, yet more preferably less than10 μg/ml, yet more preferably less than 7 μg/ml, even more preferablyless than 5 μg/ml, most preferably less than 4, less than 3, or lessthan 2 μg/ml, even more preferably less than 1 μg/ml. This allows theisolate to be administered to human beings without introducingvancomycin-resistant bacteria.

In an embodiment, the isolate taught herein is sensitive to all ofcefotaxime, erythromycin, oxacillin, teicoplanin, tobramycin andvancomycin.

In an embodiment, the isolated intestinal bacterial strain, or a strainderived therefrom as taught herein belongs to the phylum Firmicutes,preferably to the taxon Clostridium cluster IV (Ruminococcacaea;Rajilic-Stojanovic & De Vos 2014, FEMS Microbiol. Rev. 38:996-1047),more preferably to the genus Intestinimonas, even more preferably to thespecies Intestinimonas butyriciproducens.

Kläring et al. (2013, Int. J. of Syst. and Evol. Microbiol. 63:4606)disclose a mouse intestinal isolate designated Intestinimonasbutyriciproducens strain SRB-521-54 (deposited as DSM 26588). Mouseintestinal isolates are unsuitable for administration to humans.Particularly, it was found that, while both strains were capable ofproducing butyrate from sugars and lysine, the human strain AF211 wasmore efficient in these conversions than the mouse isolate. Notably,this was observed with arabinose and galactose, two sugars foundabundantly in the human but not mouse diet (unpublished data).

Pfleiderer et al. (2013, Eur. J. Clin. Microbiol. Infect. Dis. 32:1471)describe new bacterial species, one of which is designated Clostridiumanorexicus strain AP4, which now has been reclassified as“Intestinimonas butyriciproducens strain AP4” based on the 16S rRNAsequence. This strain is not publicly available, and has not beendescribed in detail.

In an embodiment, the isolated bacterial strain, or strain derivedtherefrom, as taught herein is not Intestinimonas butyriciproducensstrain ER1, and/or Intestinimonas butyriciproducens strain SRB-521-5-I(DSM 26588; a mouse intestinal isolate), and/or Clostridium anorexicusstrain AP4 (also referred to as “Intestinimonas butyriciproducens strainAP4”).

Compositions

In a third aspect, this disclosure relates to a composition comprisingany of the isolated bacterial strains, or strains derived therefrom, astaught herein and a physiologically acceptable carrier.

In an embodiment, the isolated bacterial strain, or strain derivedtherefrom, as taught herein is not Intestinimonas butyriciproducensstrain ER1, and/or Intestinimonas butyriciproducens strain SRB-521-5-I(DSM 26588), and/or Clostridium anorexicus strain AP4.

In a preferred embodiment, the composition as taught herein comprisesthe isolated intestinal bacterial strain deposited as CBS 139326 (alsoreferred to as “Intestinimonas AF211”), or a strain derived therefrom,and a physiologically acceptable carrier.

In an embodiment, the physiologically acceptable carrier may be anycarrier that is suitable for keeping the intestinal bacterial strain astaught herein viable until consumption by a subject (e.g., humans and/oranimals). For instance, non-limiting examples of acceptable carriersthat are suitable for this purpose include any of well-knownphysiological or pharmaceutical carriers, buffers, and excipients. Itwill be appreciated that the choice for a suitable physiological orpharmaceutical carrier will depend upon the intended mode ofadministration of the composition as taught herein (e.g., oral) and theintended form of the composition (e.g., beverage, yogurt, powder,capsules, and the like). The skilled person knows how to select aphysiological or pharmaceutical carrier, which is suitable for thecompositions as taught herein.

In an embodiment, the composition as taught herein may be in the form ofa food composition, feed composition, feed supplement composition, foodsupplement composition or pharmaceutical composition. The composition ispreferably suitable for consumption by a human being.

In an embodiment, the composition is a food or food supplementcomposition. The food or food supplement composition may be selectedfrom the group consisting of a liquid, liquid beverage (including dairybeverage and fermented beverage), yogurt, cheese, gel, gelatin, gelatincapsule, powder, paste, pressed tablet, and gel cap. In a suitableembodiment, the composition is a liquid, preferably a liquid beverage(e.g., dairy beverage). The food or food supplement composition may be adairy product, preferably a fermented dairy product, preferably a yogurtor a yogurt drink.

In an embodiment, the composition as taught herein may be a probioticcomposition. Such probiotic composition may comprise any of the isolatedintestinal bacterial strain as taught herein, or a strain derivedtherefrom.

In an embodiment, the composition as taught herein further comprises oneor more additional beneficial isolated intestinal bacterial strain.

In one embodiment, the one or more additional beneficial isolatedintestinal bacterial strain may be any lactic acid bacterial strainselected from the genera Lactobacillus and/or Bifidobacterium and/or anybutyrate-producing bacteria which produces butyrate via the acetyl-CoApathway.

In an embodiment, the composition may be a symbiotic composition. It maybe advantageous to add one or more prebiotic ingredients to thecomposition as taught herein, for example, to enhance the effects (e.g.,production of butyric acid and/or butyrate or a derivative thereof) ofthe intestinal bacterial strain as taught herein.

In an embodiment, the one or more prebiotic ingredients may be anyprebiotic ingredients, which are suitable to enhance the activity and/orstimulate the growth of the isolated intestinal bacterium, or a strainderived therefrom, as taught herein. Non-limiting examples of suitableprebiotic ingredients include fibers, cellobiose, maltose, mannose,salicine, trehalose, amygdalin, arabinose, melibiose, rhamnose and/orxylose.

In an embodiment, the composition as taught herein comprises alysine-rich source and/or lysine. For instance, it may be advantageousto add a lysine rich source and/or lysine to the composition as taughtherein to further promote the production of butyric acid and/or butyrateor a derivative thereof in the GI tract of a mammal (e.g., human being).

In an embodiment, the composition as taught herein may comprise one ormore ingredients which are suitable for promoting survival and/orviability of the isolated intestinal bacterial strain or strain derivedtherefrom as taught herein during storage and/or during exposure to bileand/or during passage through the GI tract of a mammal (e.g., a humanbeing). Non-limiting examples of such ingredients include an entericcoating, and controlled release agents allowing passage through thestomach. The skilled person knows how to select suitable ingredients formaintaining an isolated intestinal bacterial strain (such as any of theisolated intestinal bacterium as taught herein) viable and functional,i.e., able to carry out their intended function(s).

In one embodiment, the compositions as taught herein may furthercomprise one or more ingredients, which further enhance the nutritionalvalue and/or the therapeutic value of the compositions as taught herein.For instance, it may be advantageous to add one or more ingredients(e.g., nutritional ingredients, veterinary or medicinal agents, etc.)selected from proteins, amino acids, enzymes, mineral salts, vitamins(e.g., thiamine HCl, riboflavin, pyridoxine HCl, niacin, inositol,choline chloride, calcium pantothenate, biotin, folic acid, ascorbicacid, vitamin B12, p-aminobenzoic acid, vitamin A acetate, vitamin K,vitamin D, vitamin E, and the like), sugars and complex carbohydrates(e.g., water-soluble and water-insoluble monosaccharides, disaccharides,and polysaccharides), medicinal compounds (e.g., antibiotics),antioxidants, trace element ingredients (e.g., compounds of cobalt,copper, manganese, iron, zinc, tin, nickel, chromium, molybdenum,iodine, chlorine, silicon, vanadium, selenium, calcium, magnesium,sodium and potassium and the like). The skilled person is familiar withmethods and ingredients that are suitable to enhance the nutritionaland/or therapeutic/medicinal value of the compositions as taught herein.

The bacterial strain taught herein may be incorporated into thecomposition in lyophilized form, microencapsulated form (reviewed by,for example, Solanki et al., BioMed. Res. Int. 2013, Article ID 620719),or any other form preserving the activity and/or viability of thebacterial strain.

The composition as taught herein may be a pharmaceutical composition.The pharmaceutical composition may be for use as a supplement. Apharmaceutical composition will usually comprise a pharmaceuticalcarrier, in addition to the bacterial strain taught herein. The carrieris preferably an inert carrier. The preferred form depends on theintended mode of administration and (therapeutic) application. Apharmaceutical carrier can be any compatible, nontoxic substancesuitable to deliver bacteria of the bacterial strain taught herein tothe GI tract of a subject. For example, sterile water, or inert solidsmay be used as a carrier, usually complemented with a pharmaceuticallyacceptable adjuvant, buffering agent, dispersing agent, and the like. Apharmaceutical composition as taught herein may be in liquid form, e.g.,a stabilized suspension of bacteria of the bacterial strain taughtherein, or in solid form, e.g., a powder of lyophilized bacteria of thebacterial strain taught herein. In case the bacterial strain taughtherein is lyophilized, a cryoprotectant such as lactose, trehalose orglycogen can be employed. For example, for oral administration, bacteriaof the bacterial strain taught herein can be administered in soliddosage forms, such as capsules, tablets, and powders, comprisinglyophilized bacteria, or in liquid dosage forms, such as elixirs,syrups, and suspensions. Bacteria of the bacterial strain taught herein,e.g., in lyophilized form, can be encapsulated in capsules such asgelatin capsules, together with inactive ingredients and powderedcarriers, such as, e.g., glucose, lactose, sucrose, mannitol, starch,cellulose or cellulose derivatives, magnesium stearate, stearic acid,sodium saccharin, talcum, magnesium carbonate and the like.

In an embodiment, the intestinal bacterium or strain derived therefromas taught herein may be comprised in the composition as taught herein inan amount ranging from about 10⁶ to about 10¹⁵ colony forming units(CFU). For instance, the intestinal bacteria may be comprised in thecomposition in an amount of about 10⁷ CFU to about 10¹⁴ CFU, preferablyabout 10⁸ CFU to about 10¹³ CFU, preferably about 10⁹ CFU to about 10¹²CFU, more preferably about 10¹⁰ CFU to about 10¹² CFU.

The compositions as taught herein may be produced by any conventionalmethods.

Methods and Uses of the Invention

In another aspect, this disclosure is concerned with a bacterial strainas taught herein or a composition as taught herein for use as amedicament, for use as a food or food supplement, or for use as aprobiotic and/or symbiotic.

In yet another aspect, the disclosure pertains to a bacterial strain astaught herein or a composition as taught herein for use in maintaining,restoring and/or improving GI health in general, and/or for preventingand/or treating conditions or diseases such as cancer (e.g., colorectalcancer), IBD (e.g., Crohn's disease, ulcerative colitis), IBS, obesity,bacterial and viral diarrhea, constipation, bloating, allergies, urinarytract infections, metabolic diseases, such as metabolic syndrome andinsulin resistance or insulin resistance-related complications, such asdyslipidemia and type 2 diabetes mellitus as well as insulin-resistancein endocrine diseases (e.g., obese subjects with type 1 diabetesmellitus, Cushing's disease or lipodystrophy syndromes), cardiovasculardisease, ovarian aging, polycystic ovary syndrome, neurodegenerativedisorders, such as Alzheimer's disease, multiple sclerosis and dementia,or encephalopathy.

The disclosure is also directed to a method for maintaining, restoringand/or improving GI health in general, and/or for preventing and/ortreating conditions or diseases such as cancer (e.g., colorectalcancer), IBD (e.g., Crohn's disease, ulcerative colitis), IBS, obesity,bacterial and viral diarrhea, constipation, bloating, allergies, urinarytract infections, metabolic diseases, such as metabolic syndrome andinsulin resistance or insulin resistance-related complications, such asdyslipidemia and type 2 diabetes mellitus as well as insulin-resistancein endocrine diseases (e.g., obese subjects with type 1 diabetesmellitus, Cushing's disease or lipodystrophy syndromes), cardiovasculardisease, ovarian aging, polycystic ovary syndrome, neurodegenerativedisorders, such as Alzheimer's disease, multiple sclerosis and dementia,or encephalopathy in a subject in need thereof, the method comprisingthe step of increasing the level of a bacterial strain as taught hereinin the subject. The level of the bacterial strain as taught herein inthe subject may be increased by administering an effective amount of thebacterial strain to the subject, and/or by administering an effectiveamount of a compound capable of increasing the level of the bacterialstrain in (the GI tract of) the subject.

In a further aspect, this disclosure relates to methods for metabolizingfructose-lysine and/or for preventing and/or reducing the formation ofglycated lysine, such as fructose-lysine or other AGEs, and/or forincreasing levels of butyric acid and/or butyrate or a derivativethereof in the GI tract of a subject, the method comprising the step ofincreasing the level of the bacterial strain as taught herein in the GItract of the subject.

In an embodiment, the level of the intestinal bacterial strain or astrain derived therefrom as taught herein in the GI tract of the subjectmay be increased either by administering an effective amount of theisolated intestinal bacterial strain to the subject, or by administeringan effective amount of a compound capable of increasing the level of theintestinal bacterium in the GI tract of the subject.

The bacterial strain or a strain derived therefrom as taught herein maybe administered in the form of a composition as taught herein.

In an embodiment, the bacterial strain or a strain derived therefrom astaught herein may be administered concomitant with lysine or alysine-rich compound, such as proteins or protein fragments derived frombovine or other milks as well as plant origin such as soy, cowpea orother beans. The skilled person can, without undue burden, readilyidentify lysine-rich compounds.

In a preferred embodiment, the level of the bacterial strain or a strainderived therefrom as taught herein in the GI tract of a subject may beincreased by administering an effective amount of the bacterial strainor a strain derived therefrom as taught herein and/or compositions astaught herein, but preferably Intestinimonas AF211 and/or a compositioncomprising Intestinimonas AF211, to the subject.

In an embodiment, the subject may be selected from the group consistingof human beings, non-human primates, mice, rats, dogs, cows, and pigs.In a preferred embodiment, the subject is a human. In a specificembodiment the subject is a human with a reduced amount of butyrogenicbacteria, specifically butyrogenic bacteria of the disclosure, in the GItract.

The disclosure also relates to a method for producing butyrate, themethod comprising the step of contacting the bacterial strain as taughtherein with a suitable energy source, e.g., lysine or glucose/acetate,under conditions which allow the bacterial strain as taught herein toconvert the energy source to butyrate.

Additionally, the disclosure relates to a method for producing butyrate,the method comprising the step of contacting the bacterial strain astaught herein with fructose-lysine under conditions which allow thebacterial strain to convert the fructose-lysine to butyrate.

The methods taught herein may be in vitro methods.

This disclosure is further illustrated, but not limited, by thefollowing examples. From the above discussion and these examples, oneskilled in the art can ascertain the essential characteristics of thedisclosure, and without departing from the teaching and scope thereof,can make various changes and modifications of the disclosure to adapt itto various usages and conditions. Thus, various modifications of thedisclosure in addition to those shown and described herein will beapparent to those skilled in the art from the foregoing description.Such modifications are also intended to fall within the scope of theappended claims.

FIG. 1 shows lysine conversion and butyrate and acetate production upongrowth of AF211 on L-lysine as the sole carbon source.

EXAMPLES Example 1: Functional Analysis of Intestinimonas AF211

The goal of this study was to assess whether the strain IntestinimonasAF211 is capable of converting L-lysine into butyric acid and/orbutyrate or a derivative thereof.

Culture:

A fecal sample from a healthy subject was collected. The fecal samplewas enriched in an anaerobic bicarbonate buffered mineral salt mediumcontaining 40 mM lactate and 40 mM acetate as an energy and carbonsource. The head-space was filled with CO²/N² (1:5) at 1.5 atm andincubated at 37° C. Subsequently the strain Intestinimonas AF211 wasisolated in reinforced clostridium medium (RCM, available at Difco) inserial dilution rows and plating at least 3 times. The purification wasconfirmed by 16S rRNA gene sequencing. The strain Intestinimonas AF211was maintained in RCM medium at 37° C.

Functional Analysis:

In order to assess the ability of Intestinimonas AF211 to convertL-lysine into butyric acid and/or butyrate and derivatives, a group ofIntestinimonas AF211 was grown in a bicarbonate-buffered mediumcontaining 20 mM L-Lysine as the sole source of carbon and energy. Theability of Intestinimonas AF211 to produce butyric acid and/or butyrateor a derivative thereof was also tested in the presence of other aminoacids by growing separate groups of Intestinimonas AF211 in abicarbonate-buffered medium containing 20 mM of D-lysine, glutamate,glutamine, glycine, proline, arginine, aspartate or methionine. Anothergroup of Intestinimonas AF211 was grown in a bicarbonate-buffered mediumcontaining 20 mM of glucose, galactose, arabinose, lactose, maltose, orfructose plus acetate.

Production of butyric acid and/or butyrate, as well as other products(e.g., acetate) was assessed by High Performance Liquid Chromatography(HPLC) and OD measurement by a spectrophotometer at wavelength of 600nm. Lysine degradation was quantified on a HPLC using a Polaris C18-Acolumn (Agilent) running at 45° C. and a UV-visible detector atwavelength of 436 nm. Flow rate was 0.5 ml/minute. A2-eluent mobilephase was consisting of 24 mM acetic acid: 8% acetonitrile (pH 6.6) assolvent A and acetonitrile:2-propanol (60:40) as solvent B. The eluentgradient was set from 95% solution A and 5% solution B to 25% ofsolution A and 75% of solution B was for the first 15 minutes and eachrun was taken for 22 minutes in total. An internal standard was 4 mMnorleucine. The product formation was measured on a Thermo ScientificHPLC Spectra system equipped with a Agilent Metacarb 67H 300×6.5 mmcolumn kept at 37° C. and running with 10 mM arabinose as an eluent. Thedetector was a refractive index detector. The eluent flow was 0.8ml/minute. Gas production was performed as previously described. Allanalyses were performed in duplicate.

Intestinimonas AF211 was cultivated in a bicarbonate buffered mediumcontaining 20 mM of [2-¹³C] L-lysine or [6-¹³C]L-lysine. Labelled lysinewas purchased from Campro Scientific (Veenendaal, The Netherlands).Samples were taken from overnight growing culture and centrifuged at10000 g. Supernatants was dissolved in 0.5 mL D20 (99.9 atom %, SigmaAldrich) and were subsequently collected in NMR tubes (Camproscientific). ¹³C NMR spectra were recorded at a probe temperature of300K on a Bruker Avance-III-500 spectrometer located at the WageningenNMR Centre (WNMRC), Wageningen, the Netherlands. Chemical shifts wereexpressed in ppm relative to the C-6 of added [6-¹³C] lysine at 41.75ppm (Biological Magnetic Resonance Data Bank, the site available on theWorld Wide Web at bmrb.wisc.edu/metabolomics/metabolomics_standards).The products were identified based on chemical shifts as compared toabove database.

Results:

The results of the experiment are shown in FIG. 1. Briefly, the resultsrevealed that the strain Intestinimonas AF211 was able to convertL-lysine into butyrate. More specifically, it was found thatIntestinimonas AF211 converted approximately 16.8 mM of L-lysine into14.2 mM of butyrate and 15.6 mM of acetate (see FIG. 1). The resultsalso show that no butyrate could be produced by Intestinimonas AF211when grown in the presence of amino acids other than L-Lysine.

Example 2: Identification of the Genes Involved in the Lysine Pathway

The goal of this experiment was to determine whether IntestinimonasAF211 possesses the genes constituent of the lysine pathway. For thispurpose, the genome of Intestinimonas AF211 was sequenced using singlemolecule next generation sequencing (NCBI accession number CP009497).The results were subsequently analyzed for the presence of genesbelonging to the lysine pathway.

Genome Sequencing:

Intestinimonas AF211, which was grown in RCM (o/n), was used for DNAextraction. The DNA isolation was performed using ZR Fungal/Bacteria DNAMINIPREP™ kit (ZYMO) according to manufacturer's instructions. Genomesequencing of 15 kb library was performed with PacBio RS II instrumentusing P4/C2 chemistry (Pacific Biosciences, Menlo Park Calif., USA).Data processing and filtering was done with PacBio SMRT analysispipeline v2.2 and the Hierarchical Genome Assembly Process (HGAP)protocol (World Wide Web at pacb.com/devnet).

Results:

The results show that the genome of Intestinimonas AF211 consisted of asingle circular chromosome of 3,376,476 bp, which carried 3359 codingsequences that were annotated as NCBI accession number CP009497.Remarkably, the entire lysine pathway gene set (also referred to ascluster AF976-982) was found in Intestinimonas AF211. More specifically,genes that may be comprised in the lysine pathway gene set are listed inTable 1 below.

TABLE 1 Genes comprised in the lysine pathway gene set and detected inIntestinimonas AF211. Genes comprised in the lysine pathway gene set anddetected in Intestinimonas AF211 Locus tag  1. L-Lysine permease AF887 2. Lysine 2,3-aminomutase (EC 5.4.3.2) AF980  3. L-beta-lysine5,6-aminomutase alpha subunit AF981 (EC 5.4.3.3)  4. L-beta-lysine5,6-aminomutase beta subunit AF982 (EC 5.4.3.3)  5. 3,5-diaminobexanoatedehydrogenase (EC 1.4.1.11) AF979  6. 3-keto-5-aminohexanoate cleavageenzyme AF977  7. 3-aminobutyryl-CoA ammonia-lyase AF976  8. Butyryl-CoAdehydrogenase (EC 1.3.99.2)/Etf AF2889 to 2891  9. Butyrate-acetoacetateCoA-transferase subunit A AF3339 (EC 2.8.3.9) 10. Butyrate-acetoacetateCoA-transferase subunit B AF3340 (EC 2.8.3.9) 11.Acetyl-CoA:acetoacetyl-CoAtransferase (EC 2.8.3.8) AF155 12.3-ketoacyl-CoA thiolase (EC 2.3.1.16)/Acetyl-CoA AF3338acetyltransferase (EC 2.3.1.9) 13. Phosphate acetyltransferase (EC2.3.1.8) AF212 14. Acetate kinase (EC 2.7.2.1) AF1052 15. Proton pumpingRnf cluster (A, B, C, D, E, G AF682 to 687 subunits) 16. V-type ATPsynthase cluster (A, B, C, D, E, F, I, K AF3050 to 3057 subunits) 17.Inorganic Pyrophosphatase (EC 3.6.1.1) AF2617 18. Ammonium transporterAF653, AF1882, AF1747, AF2982, AF3082, AF3208 19. Putative short chainfatty acids transporter AF191, AF924, AF1158 20. Na+/H+ antiporterAF1159, AF2156, AF3116

Example 3: Proteomic Analysis of the Lysine Utilization Pathway

In order to assess whether Intestinimonas AF211 is able to produce theproteins encoded by the genes of the lysine degradation pathway (seeTable 1, Example 2), the following experiment was performed:

Culture:

A first group of Intestinimonas AF211 was grown on in 500 ml ofbicarbonate buffer medium comprising 20 mM L-lysine as the sole sourceof carbon and energy. A second group of Intestinimonas AF211 was grownin 500 ml of bicarbonate buffer medium comprising 40 mM glucose and 40mM of sodium acetate (GA) as the sole source of carbon and energy. In asubsequent step, the proteins produced by both groups were harvested bycollecting Intestinimonas AF211 of each experimental condition in theexponential phase by centrifugation at 10000×g at 4° C. for 20 minutes.The pellets obtained were subsequently washed twice in 100 mM Tris-HCl,pH 7.5, 1 mM dithioerythreitol (DTE) and suspended in 1 ml of SDT-lysisbuffer, which contained 100 mM Tris/HCl pH 7.5, 4% SDS and 0.1 Mdithiotreitol. In a subsequent step the proteins were extractedaccording to the method of Bennett et al. (1995), FEMS MicrobiologyReviews, Vol: 17, pages 241-249. The abundance of the proteins extractedfrom each of the experimental conditions was investigated with LC-MS/MS.

Protein Analysis:

A quantitative proteomics analysis was carried out a on the cytoplasmicprotein fraction. For this purpose, an Intestinimonas AF211 database wasdeduced from its genome sequence and used together with a contaminantdatabase, which contained sequences of common contaminants, forinstance, BSA, trypsin, keratin, bovine serum albumin. The proteomicsresult contained peptides and proteins with a false discovery rate (FDR)of less than 1% and proteins with at least two identified peptides ofwhich should be unique and one should be unmodified without any reversedhits. The normal logarithm was taken from protein label freequantitation (LFQ) intensities. Zero “Log LFQ” values were replaced by avalue of 5.4 (just below the lowest value) to make sensible ratiocalculations possible. Relative protein quantitation of sample tocontrol was done with Perseus 1.3.0.4 by applying a two sample T-testusing the “LFQ intensity” columns obtained with FDR set to 0.05 and S0set to 1. Total non-normalized protein intensities corrected for thenumber of measurable tryptic peptides were giving intensity basedabsolute quantitation intensity (iBAQ). Total proteins were quantifiedusing QUBIT® 2.0 Fluorometer (Invitrogen) according to manufacturer'sinstructions.

Results:

The results of the proteomic analysis revealed that Intestinimonas AF211is able to produce all proteins involved in the conversion of L-lysineinto butyrate and employed the lysine utilization pathway as taughtherein (i.e., encoded by genes comprised in the Lysine pathway gene setAF976-982; see Table 1, Example 2). The results also show thatIntestinimonas AF211 was able to produce all proteins involved in theconversion of glucose and acetate into butyrate and employed theacetyl-CoA pathway, similar to other members of Clostridium cluster IV.Taken together, these results indicate that Intestinimonas AF211comprises both the lysine utilization pathway (as taught herein) and theconventional acetyl-CoA pathway.

Moreover, it was found that the production of proteins encoded by thelysine pathway genes was up-regulated when Intestinimonas AF211 wasgrown in the presence of L-lysine as the sole source of carbon andenergy as compared to when Intestinimonas AF211 was grown in thepresence of equimolar amounts of glucose and acetate (GA) as the solesource of carbon and energy. For instance, it was observed by thepresent inventors that the following proteins were upregulated in thepresence of L-lysine relative to GA as the sole carbon source:acetyl-CoA: acetoacetyl-CoA transferase (4.08-fold increase); phosphateacetyltransferase (3.25-fold increase), 3-keto-5-aminohexanoate cleavageenzyme (10.87-fold increase); 3,5-diaminobexanoate dehydrogenase(7.07-fold increase); lysine 2,3-aminomutase (11.11-fold increase);L-beta-lysine 5,6-aminomutase alpha subunit (6.25-fold increase);L-beta-lysine 5,6-aminomutase beta subunit (11.26-fold increase);acetate kinase (2.83-fold increase); 3-ketoacyl-CoA thiolase/Acetyl-CoAacetyltransferase (1.34-fold increase); butyrate-acetoacetateCoA-transferase (1.57-fold increase); and butyrate-acetoacetateCoA-transferase beta subunit (2.03-fold increase).

Example 4: Metabolism of Amadori Glycated Products

The goal of this experiment was to assess whether Intestinimonas AF211was capable of growing efficiently on a medium comprisingfructose-lysine and whether Intestinimonas AF211 was able to convertfructose-lysine into butyrate. Further, the genome of IntestinimonasAF211 was analyzed and screened for the presence of the genes comprisedin the fructose-lysine uptake and degradation operon.

Functional Analysis:

In order to assess whether Intestinimonas AF211 is able to metabolizeAmadori glycated lysine (fructose-lysine), Intestinimonas AF211 wasgrown in a bicarbonate medium comprising 20 mM of fructose-lysine for aduration of 4 days.

Results:

The results of the genome analysis revealed that Intestinimonas AF211possesses an operon-like cluster with genes for fructose-lysine uptakeand degradation (AF949-955). The genes are listed in Table 2 below.

The results of the functional analysis reveal that Intestinimonas AF211was not only capable of growing efficiently on a fructose-lysinesubstrate but was also able to convert fructose-lysine into butyrate.More specifically, it was shown that Intestinimonas AF211 was able toconvert 20 mM of fructose-lysine into 16.4 mM of butyrate, 0.2 mM ofacetate, and 9.4 mM of ammonium (NH₄+) over a period of 4 days.

TABLE 2 The Fructose-lysine uptake and degradation pathway Genescomprised in the fructose-lysine uptake and degradation operon anddetected in Intestinimonas AF211 Locus tag 1. Fructose-lysine kinaseAF949 2. Fructoselysine 3-epimerase AF950 3. Fructosamine deglycaseAF951 4. ABC transporter periplasmic spermidine AF952 putrescine-bindingprotein PotD 5. Spermidine Putrescine ABC transporter AF953 permeasecomponent PotC 6. Spermidine putrescine ABC transporter AF954 permeasecomponent PotB 7. Putrescine transport ATP-binding protein PotA AF955

Example 5: Proteomic Analysis of the Fructose-Lysine Uptake andDegradation Pathway

In order to assess whether Intestinimonas AF211 was able to produce theproteins encoded by the genes of the fructose-lysine uptake anddegradation pathway (see Table 2, Example 4), the following experimentwas performed:

Culture:

A first group of Intestinimonas AF211 was grown in 500 ml of bicarbonatebuffer medium comprising 20 mM of lysine as the sole source of carbonand energy. A second group of Intestinimonas AF211 was grown in 500 mlof bicarbonate buffer medium comprising 40 mM glucose and 40 mM ofsodium acetate (GA) as the sole source of carbon and energy. In asubsequent step, the proteins produced by both groups were harvested bycollecting Intestinimonas AF211 of each experimental condition in theexponential phase by centrifugation at 10000×g at 4° C. for 20 minutes.The pellets obtained were subsequently washed twice in 100 mM Tris-HCl,pH 7.5, 1 mM dithioerythreitol (DTE) and suspended in 1 ml of SDT-lysisbuffer, which contained 100 mM Tris/HCl pH 7.5, 4% SDS and 0.1 Mdithiotreitol. In subsequent steps, the proteins were extractedaccording to the method of Bennett et al. (1995), FEMS MicrobiologyReviews, Vol: 17, pages 241-249. The abundance of the proteins extractedfrom each of the experimental conditions were investigated withLC-MS/MS.

Protein Analysis:

A quantitative proteomics analysis was carried out a on the cytoplasmicprotein fraction as set out in Example 3 above.

Results:

The results of the proteomic analysis revealed that Intestinimonas AF211is also able to produce all proteins involved in the conversion offructose-lysine into butyrate and employed the fructose-lysine uptakeand degradation pathway as taught herein (see Table 2, Example 3).

Moreover, it was found that the production of proteins encoded by thefructose-lysine uptake and degradation pathway genes as taught hereinwere up-regulated when Intestinimonas AF211 was grown in the presence oflysine as the sole source of carbon and energy compared to whenIntestinimonas AF211 was grown in the presence of GA as the sole sourceof carbon and energy. For instance, it was observed by the presentinventors that the following proteins were upregulated in the presenceof lysine relative to GA: fructose-lysine kinase (16.51-fold increase);fructosamine deglycase (9.42-fold increase); ABC transporter periplasmicspermidine putrescine-binding protein PotD (2.78-fold increase);spermidine putrescine ABC transporter permease component PotC (24.8-foldincrease); and putrescine transport ATP-binding protein PotA (20.21-foldincrease).

Example 6: Antibiotic Sensitivity of Intestinimonas Strain AF211

Rettedal et al. (Nature Comm. (2014), 5:4714) describe the use ofantibiotics to isolate and culture bacteria from the human intestinaltract. However, this approach often results in antibiotic-resistantbacteria and these are undesired in formulations aimed for human oranimal use. The Intestinimonas strain P1C2 that was isolated wasdescribed as resistant to erythromycin (MIC 32 ug/ml), an macrolideantibiotic often used in humans. Hence, the sensitivity ofIntestinimonas strain AF211 against erythromycin was determined. It wasfound that strain AF211 was sensitive to erythromycin, having an MIC of1 μg/ml erythromycin.

Strain AF211 had the following sensitivity to various antibiotics:

Antibiotic MIC (μg/ml) Cefotaxime 0.064-0.05  Erythromycin 0.75-1  Oxacillin 0.38 Teicoplanin 0.047 Tobramycin 2 Vancomycin 0.75

The invention claimed is:
 1. A method of providing treatment ofmetabolic syndrome in a subject, the method comprising: administering tothe subject a bacterium comprising: a lysine pathway gene set thatenables said bacterium to convert L-lysine into butyric acid, butyrate,or a combination or derivative thereof, and a glycated lysine uptake anddegradation operon that enables said bacterium to convert glycatedlysine into butyric acid, butyrate, or a combination or derivativethereof, wherein the lysine pathway gene set encodes at least one ofLysine 2,3-aminomutase, L-beta-lysine 5,6-aminomutase alpha subunit,L-beta-lysine 5,6-aminomutase beta subunit, 3,5-diaminobexanoatedehydrogenase, 3-keto-5-aminohexanoate cleavage enzyme,3-aminobutyryl-CoA ammonia-lyase, butyrateacetoacetate CoA-transferasesubunit A, butyrate-acetoacetate CoA-transferase subunit B, andacetyl-CoA:acetoacetyl-CoA transferase; and wherein the glycated lysineuptake and degradation operon is a fructose-lysine uptake anddegradation operon encoding at least one of fructose-lysine kinase,fructosamine deglycase, ABC transporter periplasmic spermidineputrescine-binding protein PotD, spermidine putrescine ABC transporterpermease component PotC, spermidine putrescine ABC transporter permeasecomponent PotB, and putrescine transport ATP-binding protein PotA. 2.The method according to claim 1, wherein when the bacterium is grown onL-lysine as the sole carbon source as compared to when the bacterium isgrown on equimolar amounts of glucose and acetate as sole carbon source,expression of at least one of the genes encoding the proteins: Lysine2,3-aminomutase, L-beta-lysine 5,6-aminomutase alpha subunit,L-beta-lysine 5,6-aminomutase beta subunit, 3,5-diaminobexanoatedehydrogenase, 3-keto-5-aminohexanoate cleavage enzyme,3-aminobutyryl-CoA ammonia-lyase, butyrate-acetoacetate CoA-transferasesubunit A, butyrate-acetoacetate CoA-transferase subunit B, andacetyl-CoA: acetoacetyl-CoA transferase, is upregulated; and/or at leastone of the proteins: Lysine 2,3-aminomutase, L-beta-lysine5,6-aminomutase alpha subunit, L-beta-lysine 5,6-aminomutase betasubunit, 3,5-diaminobexanoate dehydrogenase, 3-keto-5-aminohexanoatecleavage enzyme, 3-aminobutyryl-CoA ammonia-lyase, butyrate-acetoacetateCoA-transferase subunit A, butyrate-acetoacetate CoA-transferase subunitB, and acetyl-CoA:acetoacetyl-CoA transferase, is overexpressed.
 3. Themethod according to claim 1, wherein the glycated lysine isfructose-lysine, and wherein the glycated lysine uptake and degradationoperon is a fructose-lysine uptake and degradation operon.
 4. The methodaccording to claim 3, wherein the fructose-lysine uptake and degradationoperon comprises a gene encoding fructose-lysine 3-epimerase.
 5. Themethod according to claim 1, wherein when the bacterium is grown onL-lysine as the sole carbon source as compared to when the bacterium isgrown on equimolar amounts of glucose and acetate as sole carbon source,expression of at least one of the genes encoding the proteins:fructose-lysine kinase, fructoselysine 3-epimerase, fructosaminedeglycase, ABC transporter periplasmic spermidine putrescine-bindingprotein PotD, spermidine putrescine ABC transporter permease componentPotC, spermidine putrescine ABC transporter permease component PotB,putrescine transport ATP-binding protein PotA, is upregulated; and/or atleast one of the proteins: fructose-lysine kinase, fructoselysine3-epimerase, fructosamine deglycase, ABC transporter periplasmicspermidine putrescine-binding protein PotD, spermidine putrescine ABCtransporter permease component PotC, spermidine putrescine ABCtransporter permease component PotB, putrescine transport ATP-bindingprotein PotA, is overexpressed.
 6. The method according to claim 1,wherein the bacterium is sensitive to erythromycin, having a minimuminhibitory concentration of erythromycin of less than 20 μg/ml.
 7. Themethod according to claim 1, wherein the glycated lysine isfructose-lysine, and wherein the glycated lysine uptake and degradationoperon is a fructose-lysine uptake and degradation operon.
 8. The methodaccording to claim 3, wherein the fructose-lysine uptake and degradationoperon comprises one or more of the genes encoding the proteins:fructose-lysine kinase, fructose-lysine 3-epimerase, fructosaminedeglycase, ABC transporter periplasmic spermidine putrescine-bindingprotein PotD, spermidine putrescine ABC transporter permease componentPotC, spermidine putrescine ABC transporter permease component PotB, andputrescine transport ATP-binding protein PotA.
 9. The method accordingto claim 8, wherein when the bacterium is grown on L-lysine as the solecarbon source as compared to when the bacterium is grown on equimolaramounts of glucose and acetate as sole carbon source, expression of atleast one of the genes encoding the proteins: fructose-lysine kinase,fructoselysine 3-epimerase, fructosamine deglycase, ABC transporterperiplasmic spermidine putrescine-binding protein PotD, spermidineputrescine ABC transporter permease component PotC, spermidineputrescine ABC transporter permease component PotB, putrescine transportATP-binding protein PotA, is upregulated; and/or at least one of theproteins: fructose-lysine kinase, fructoselysine 3-epimerase,fructosamine deglycase, ABC transporter periplasmic spermidineputrescine-binding protein PotD, spermidine putrescine ABC transporterpermease component PotC, spermidine putrescine ABC transporter permeasecomponent PotB, putrescine transport ATP-binding protein PotA, isoverexpressed.
 10. The method according to claim 2, wherein the glycatedlysine is fructose-lysine, and wherein the glycated lysine uptake anddegradation operon is a fructose-lysine uptake and degradation operon.11. The method according to claim 10, wherein the fructose-lysine uptakeand degradation operon comprises one or more of the genes encoding theproteins: fructose-lysine kinase, fructose-lysine 3-epimerase,fructosamine deglycase, ABC transporter periplasmic spermidineputrescine-binding protein PotD, spermidine putrescine ABC transporterpermease component PotC, spermidine putrescine ABC transporter permeasecomponent PotB, and putrescine transport ATP-binding protein PotA. 12.The method according to claim 1, wherein the fructose-lysine uptake anddegradation operon further comprises the gene encoding the proteinfructose-lysine 3-epimerase.
 13. The method according to claim 1,wherein the bacterium colonizes the large intestine of the subject. 14.The method according to claim 1, wherein the treatment maintains,restores, and/or improves the subject's gastrointestinal health.
 15. Themethod according to claim 1, wherein the lysine pathway gene set encodeseach of Lysine 2,3-aminomutase, L-beta-lysine 5,6-aminomutase alphasubunit, L-beta-lysine 5,6-aminomutase beta subunit,3,5-diaminobexanoate dehydrogenase, 3-keto-5-aminohexanoate cleavageenzyme, 3-aminobutyryl-CoA ammonia-lyase, butyrateacetoacetateCoA-transferase subunit A, butyrate-acetoacetate CoA-transferase subunitB, and acetyl-CoA:acetoacetyl-CoA transferase; and wherein thefructose-lysine uptake and degradation operon encode each offructose-lysine kinase, fructosamine deglycase, ABC transporterperiplasmic spermidine putrescine-binding protein PotD, spermidineputrescine ABC transporter permease component PotC, spermidineputrescine ABC transporter permease component PotB, and putrescinetransport ATP-binding protein PotA.
 16. The method according to claim15, wherein the fructose-lysine uptake and degradation operon furtherencodes fructose-lysine 3-epimerase.
 17. A method of treating a subjectfor metabolic syndrome, wherein the subject has a large intestine, themethod comprising: administering to the subject a bacterium, wherein thebacterium is Intestinimonas AF211 deposited on Jan. 5, 2015 at theCentraalbureau voor Schimmelcultures located in Utrecht, theNetherlands, and assigned deposit number CBS 139326 or a strain derivedtherefrom.
 18. The method according to claim 17, wherein the bacteriumcolonizes the large intestine of the subject.
 19. The method accordingto claim 17, wherein the treatment maintains, restores, and/or improvesthe subject's gastrointestinal health.